ERBB2 and cancer: Eradication of HER2-expressing cells by trastuzumab could result in the emergence of HER2-negative clones, as previously reported in approximately 30% of patients with initially HER2+ EG cancers who received trastuzumab-containing first-line chemotherapy regimens [4,19].